Premium
Acute and chronic neutropenias. What is new?
Author(s) -
Palmblad J.,
Papadaki H. A.,
Eliopoulos G.
Publication year - 2001
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.2001.00915.x
Subject(s) - medicine , neutropenia , immunology , immune system , monoclonal antibody , lymphocyte , antibody , chemotherapy
. Palmblad J, Papadaki HA, Eliopoulos G (The Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden and University of Crete Medical School, Heraklion, Greece). Acute and chronic neutropenias. What is new? J Intern Med 2001; 250: 476–491. Recently, some of the mechanisms and consequences in the severe chronic neutropenias (e.g. the neutrophil elastase gene mutations and the risk to progress to myelodysplasia and acute leukaemia) and in drug‐induced agranulocytosis (e.g. the apoptosis‐inducing ability of metabolites of clozapine) have been elucidated, and new aspects of autoimmune and the large granular lymphocyte syndrome were described (e.g. aberrant elaboration of Fas‐ligand causing neutrophil apoptosis). Investigations of the mild to moderate chronic neutropenias have shown the significance of interactions between the myeloid development and the immune network (e.g. relations to immunoglobulin aberrations). Granulocyte‐colony stimulation factor (G‐CSF) is widely used in patients with severe chronic neutropenia, however, its use in other conditions is mostly based on anecdotal evidence. In addition, immune modulating regimens, such as metothrexate, ciclosporine and monoclonal antibodies, are increasingly employed for the autoimmune neutropenias.